[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"opioid-induced-constipation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:opioid-induced-constipation":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100585096",false,"NCT06897917","Real World Study of Oxycodone\u002FNaloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain","Inclusion Criteria:\n\n* Age ≥ 18 years old, with a histological or pathological diagnosis of advanced cancer.\n* Be diagnosed with severe (NRS ≥ 7 points) cancer pain, requiring regular opioid therapy.\n* Diagnosed with OIC according to the Rome IV diagnostic criteria for OIC, with a BFI score ≥ 30.\n* Determined by the investigator to be eligible for treatment with oxycodone\u002Fnaloxone sustained-release tablets.\n* Estimated survival period of more than 3 months.\n* Voluntarily sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients with contraindications to oxycodone\u002Fnaloxone sustained-release tablets (including allergy to the active ingredients or any excipients of this product; severe respiratory depression accompanied by hypoxemia and\u002For hypercapnia; severe chronic obstructive pulmonary disease; pulmonary heart disease; severe bronchial asthma; paralytic ileus caused by non-opioid drugs; moderate to severe liver function impairment).\n* Patients with structural malformations of the gastrointestinal tract (such as intestinal obstruction, stenosis), other known gastrointestinal diseases\u002Fsymptoms (including cancer metastasis to the digestive tract), or gastrointestinal digestion and absorption disorders.\n* Patients with language communication barriers, cognitive impairments or mental illnesses, intracranial metastasis of tumors with consciousness disorders, or consciousness disorders caused by other reasons.\n* Other situations that the investigator judges as unsuitable for inclusion in the study.","ALL","18 Years",{"count":17,"type":18},203,"ESTIMATED","INTERVENTIONAL",[21],"PHASE4","This study is a prospective, single-arm, multicenter, real-world study to evaluate effect of bowel function, analgesic effect, quality of life, and safety of Mimeixin® in Chinese patients with severe cancer pain.",[24,25],"Opioid-Induced Constipation","Pain Cancer",[27,28,29],"opioid-induced constipation","severe cancer pain","Oxycodone\u002Fnaloxone sustained-release tablets","NOT_YET_RECRUITING","2025-03-26",{"date":33,"type":34},"2025-03-27","ACTUAL",{"date":36,"type":18},"2025-04",{"date":38,"type":18},"2025-12",{"name":40,"class":41},"Henan Cancer Hospital","OTHER_GOV",1,{"id":44,"slug":4,"hasResults":10,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":42},"100341057","NCT03720613","Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation","Risk of Major Adverse Cardiovascular Events Among Users of Naldemedine Compared With Other Medications Used for Opioid Induced Constipation in Adult Patients With Chronic Non-Cancer Pain in a Healthcare Claims Database","Inclusion Criteria:\n\n* At least one dispensing of naldemedine or lubiprostone or naloxegol without prior use in the database of either medication (index date)\n* At least two dispensings of opioids within six months prior to and including the index date, with at least a combined 31 cumulative days supply\n* At least 18 years of age or older on the index date\n* At least six months of continuous health plan coverage that includes medical and pharmacy benefits prior to and including the index date\n\nExclusion Criteria:\n\n* Any acute MACE (non-fatal MI or non-fatal stroke) within six months before or on the index date\n* Any cancer treatment or cancer pain diagnosis within six months before or on the index date\n* Prior use of methylnaltrexone, alvimopan or naloxegol within six months before or on the index date",{"count":50,"type":18},34532,"OBSERVATIONAL","The research objective is to characterize the risk of a major adverse cardiovascular event (MACE) among new users of naldemedine versus new users of lubiprostone and new users of naloxegol as comparator opioid induced constipation (OIC) medications.",[54],"Opioid-induced Constipation",[56,57,58,59,60],"naloxegol","major adverse cardiovascular event (MACE)","opioid induced constipation (OIC)","lubiprostone","naldemedine","RECRUITING","2025-02-10",{"date":64,"type":34},"2025-02-12",{"date":66,"type":34},"2019-01-04",{"date":68,"type":18},"2030-11-01",{"name":70,"class":71},"BioDelivery Sciences International","INDUSTRY",""]